|
1
|
Zhang Y, Wang W, Lv M, Lin Z, Geng J, Li
Y, Shen B, Ma Y, Li Y, Qiao C and Feng J: A single-chain antibody
using LoxP511 as the linker enables large-content phage library
construction via Cre/LoxP recombination. J Biomol Screen.
19:839–846. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang GM, Chen YP, Guan YZ, Wang Y and An
YQ: Modification and identification of a vector for making a large
phage antibody library. Chin Med J (Engl). 120:2011–2016. 2007.
View Article : Google Scholar
|
|
3
|
Baragetti A, Grejtakova D, Casula M,
Olmastroni E, Jotti GS, Norata GD, Catapano AL and Bellosta S:
Proprotein convertase subtilisin-Kexin type-9 (PCSK9) and
triglyceride-rich lipo-protein metabolism: Facts and gaps.
Pharmacol Res. 130:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abifadel M, Varret M, Rabès JP, Allard D,
Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich
D, et al: Mutations in PCSK9 cause autosomal dominant
hypercholesterolemia. Nat Genet. 34:154–156. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cohen J, Pertsemlidis A, Kotowski IK,
Graham R, Garcia CK and Hobbs HH: Low LDL cholesterol in
individuals of African descent resulting from frequent nonsense
mutations in PCSK9. Nat Genet. 37:161–165. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang CC, Fornage M, Lloyd-Jones DM, Wei
GS, Boerwinkle E and Liu K: Longitudinal association of PCSK9
sequence variations with low-density lipoprotein cholesterol
levels: The Coronary Artery Risk Development in Young Adults Study.
Circ Cardiovasc Genet. 2:354–361. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Frank-Kamenetsky M, Grefhorst A, Anderson
NN, Racie TS, Bramlage B, Akinc A, Butler D, Charisse K, Dorkin R,
Fan Y, et al: Therapeutic RNAi targeting PCSK9 acutely lowers
plasma cholesterol in rodents and LDL cholesterol in nonhuman
primates. Proc Natl Acad Sci USA. 105:11915–11920. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ray KK, Stoekenbroek RM, Kallend D, Leiter
LA, Landmesser U, Wright RS, Wijngaard P and Kastelein JJP: Effect
of an siRNA therapeutic targeting PCSK9 on atherogenic
lipoproteins: Prespecified secondary end points in ORION 1.
Circulation. 138:1304–1316. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Duff CJ, Scott MJ, Kirby IT, Hutchinson
SE, Martin SL and Hooper NM: Antibody-mediated disruption of the
interaction between PCSK9 and the low-density lipoprotein receptor.
Biochem J. 419:577–584. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dubuc G, Chamberland A, Wassef H, Davignon
J, Seidah NG, Bernier L and Prat A: Statins upregulate PCSK9, the
gene encoding the proprotein convertase neural apoptosis-regulated
convertase-1 implicated in familial hypercholesterolemia.
Arterioscler Thromb Vasc Biol. 24:1454–1459. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Careskey HE, Davis RA, Alborn WE, Troutt
JS, Cao G and Konrad RJ: Atorvastatin increases human serum levels
of proprotein convertase subtilisin/kexin type 9. J Lipid Res.
49:394–398. 2008. View Article : Google Scholar
|
|
12
|
Tonikian R, Zhang Y, Boone C and Sidhu SS:
Identifying specificity profiles for peptide recognition modules
from phage-displayed peptide libraries. Nat Protoc. 2:1368–1386.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lakzaei M, Rasaee MJ, Fazaeli AA and
Aminian M: A comparison of three strategies for biopanning of
phage-scFv library against diphtheria toxin. J Cell Physiol.
234:9486–9494. 2019. View Article : Google Scholar
|
|
14
|
Tohidkia MR, Sepehri M, Khajeh S, Barar J
and Omidi Y: Improved soluble ScFv ELISA screening approach for
antibody discovery using phage display technology. SLAS Discov.
22:1026–1034. 2017.PubMed/NCBI
|
|
15
|
Grozdanov PN, Petkov PM, Karagyozov LK and
Dabeva MD: Expression and localization of PCSK9 in rat hepatic
cells. Biochem Cell Biol. 84:80–92. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lipari MT, Li W, Moran P, Kong-Beltran M,
Sai T, Lai J, Lin SJ, Kolumam G, Zavala-Solorio J, Izrael-Tomasevic
A, et al: Furin-cleaved proprotein convertase subtilisin/kexin type
9 (PCSK9) is active and modulates low density lipoprotein receptor
and serum cholesterol levels. J Biol Chem. 287:43482–43491. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rodriguez F and Harrington RA:
Cholesterol, cardiovascular risk, statins, PCSK9 inhibitors, and
the future of LDL-C lowering. JAMA. 316:1967–1968. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harada LM, Carrilho AJ, Oliveira HC,
Nakandakare ER and Quintão EC: Regulation of hepatic cholesterol
metabolism in CETP/LDLr mice by cholesterol feeding and by drugs
(chole-styramine and lovastatin) that lower plasma cholesterol.
Clin Exp Pharmacol Physiol. 33:1209–1215. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cao Y, Yang H, Zhou X, Mao H, Gao T, Hu Z,
He L, Pan F and Guo Z: Selection and characterization of human
PCSK9 antibody from phage displayed antibody library. Biochem Bioph
Res Commun. 463:712–718. 2015. View Article : Google Scholar
|
|
20
|
Lie J, de Crom R, van Gent T, van Haperen
R, Scheek L, Sadeghi-Niaraki F and van Tol A: Elevation of plasma
phospholipid transfer protein increases the risk of atherosclerosis
despite lower apolipoprotein B-containing lipoproteins. J Lipid
Res. 45:805–811. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rashid S, Curtis DE, Garuti R, Anderson
NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA and Horton JD: Decreased
plasma cholesterol and hypersensitivity to statins in mice lacking
Pcsk9. Proc Natl Acad Sci USA. 102:5374–5379. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schroeder KM, Beyer TP, Hansen RJ, Han B,
Pickard RT, Wroblewski VJ, Kowala MC and Eacho PI: Proteolytic
cleavage of antigen extends the durability of an anti-PCSK9
monoclonal antibody. J Lipid Res. 56:2124–2132. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Barale C, Bonomo K, Frascaroli C, Morotti
A, Guerrasio A, Cavalot F and Russo I: Platelet function and
activation markers in primary hypercholesterolemia treated with
anti-PCSK9 mono-clonal antibody: A 12-month follow-up. Nutr Metab
Cardiovasc Dis. 30:282–291. 2020. View Article : Google Scholar
|
